POLR1A

DNA-directed RNA polymerase I subunit RPA1

4,894 patent compounds predicted against POLR1A, 3,098 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7506933	0.76	18/20
SCHEMBL7500170	0.73	18/20
SCHEMBL7496170	0.71	17/20
SCHEMBL7500181	0.71	17/20
SCHEMBL7499404	0.71	17/20
SCHEMBL7503807	0.76	16/20
SCHEMBL7505939	0.76	16/20
SCHEMBL7504121	0.68	16/20
SCHEMBL7504818	0.68	16/20
SCHEMBL7498213	0.56	15/20
SCHEMBL4087988	0.55	10/20
SCHEMBL635319	0.56	8/20
SCHEMBL7505575	0.47	8/20
SCHEMBL10027265	0.59	7/20
SCHEMBL7498198	0.49	7/20
SCHEMBL4571259	0.42	6/20
SCHEMBL634175	0.55	5/20
SCHEMBL634104	0.50	5/20
SCHEMBL2227397	0.47	5/20
SCHEMBL2229239	0.47	5/20

Germline variants in POLR1A on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full POLR1A gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to POLR1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors	PHASE1	WITHDRAWN
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC	EARLY_PHASE1	RECRUITING
Chromosomal Translocations in Chandigarh Police	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome)	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Impact of Bariatric and Metabolic Surgery on the Reduction of Premature Aging.	nan	COMPLETED
Cohort of Tumors With POLE/D1 Mutation	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a POLR1A binder may also engage these)

Protein	Name	Similarity
O35134	—	1.000	O35134 →
O54889	—	0.998	O54889 →
P08775	—	0.996	P08775 →
G3MZY8	—	0.996	G3MZY8 →
P35084	—	0.993	P35084 →
P11414	—	0.993	P11414 →
POLR2A	DNA-directed RNA polymerase II subunit RPB1	0.993	landscape →
P04050	—	0.992	P04050 →
A5DCV3	—	0.992	A5DCV3 →
P35074	—	0.992	P35074 →
P04052	—	0.991	P04052 →
Q75A34	—	0.991	Q75A34 →
P10964	—	0.990	P10964 →
P36594	—	0.990	P36594 →
P91875	—	0.988	P91875 →
Q9SVY0	—	0.987	Q9SVY0 →
P16356	—	0.985	P16356 →
A4IF62	—	0.983	A4IF62 →
P15398	—	0.983	P15398 →
Q9LK40	—	0.981	Q9LK40 →
P17546	—	0.981	P17546 →
Q86H36	—	0.981	Q86H36 →
Q8SSC4	—	0.980	Q8SSC4 →
P41556	—	0.980	P41556 →
Q5D869	—	0.980	Q5D869 →
P17545	—	0.980	P17545 →
Q3V1U8	—	0.979	Q3V1U8 →
P14248	—	0.978	P14248 →
Q9LV32	—	0.978	Q9LV32 →
Q5ZL98	—	0.978	Q5ZL98 →